RxDoctor Payments Data

Wally Werner, MD

Internal Medicine · Alcoa, TNNPI 1780762997

Payments from drug & device makers

$825in general payments, 2019–2025

Across 46 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$174
  • AstraZeneca$169
  • GSK$94
  • Lilly USA, LLC$90
  • AbbVie$60
  • Amgen$41
  • plus $197 from 8 others

What the payments were for

  • Food & beverage$825100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$825 in reported general payments places this provider in the 65th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$111,728
Medicare patients
220
Services billed
1,703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban121$118,784
OzempicSemaglutide63$104,443
MounjaroTirzepatide43$59,447
JardianceEmpagliflozin40$39,527
MyrbetriqMirabegron34$26,574
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$26,090
LinzessLinaclotide31$22,865
XareltoRivaroxaban16$17,562
JanuviaSitagliptin Phosphate12$14,766
Repatha SureclickEvolocumab13$11,298
Colesevelam Hcl27$6,983
SymbicortBudesonide/Formoterol Fumarate15$5,126
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$4,038
Atorvastatin Calcium459$3,998
Cevimeline Hcl27$3,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36$118,784121 claims
Novo NordiskOzempic$174$104,44363 claims
Lilly USA, LLCMounjaro$90$59,44743 claims
Boehringer IngelheimJardiance$14$39,52740 claims
Astellas Pharma US IncMyrbetriq$17$26,57434 claims
GSKTrelegy Ellipta$94$26,09025 claims
AbbVieLinzess$60$22,86531 claims
Johnson & JohnsonXarelto$33$17,56216 claims
MerckJanuvia$33$14,76612 claims
AstraZenecaSymbicort$169$5,12615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Alcoa

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →